CO2022010430A2 - Método para el tratamiento del síndrome de usher y composición del mismo - Google Patents

Método para el tratamiento del síndrome de usher y composición del mismo

Info

Publication number
CO2022010430A2
CO2022010430A2 CONC2022/0010430A CO2022010430A CO2022010430A2 CO 2022010430 A2 CO2022010430 A2 CO 2022010430A2 CO 2022010430 A CO2022010430 A CO 2022010430A CO 2022010430 A2 CO2022010430 A2 CO 2022010430A2
Authority
CO
Colombia
Prior art keywords
rna
arrna
target
target rna
usher syndrome
Prior art date
Application number
CONC2022/0010430A
Other languages
English (en)
Inventor
Pengfei Yuan
Yanxia Zhao
Nengyin Liu
Zexuan Yi
Gangbin Tang
Original Assignee
Edigene Therapeutics Beijing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edigene Therapeutics Beijing Inc filed Critical Edigene Therapeutics Beijing Inc
Publication of CO2022010430A2 publication Critical patent/CO2022010430A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Se provee un método para la edición dirigida de ARN diana que contiene una mutación G a A en un transcrito de gen USH2A con base en tecnología LEAPER, que comprende: introducir un constructo de un ARN de reclutamiento de adenosina desaminasa (arARN) para editar el ARN diana o un constructo que codifica dicho arARN en una célula, en donde el arARN comprende una secuencia de ARN complementaria que se hibrida al ARN diana, y en donde el arARN es capaz de reclutar adenosina desaminasa que actúa en el ARN (ADAR), de modo que la adenosina diana en el ARN diana es desaminada, realizando de este modo la edición in vivo de la base de A a I en el ARN de manera segura y eficaz, reparando un sitio de mutación patogénica, y logrando el propósito de tratar una enfermedad tal como el síndrome de Usher.
CONC2022/0010430A 2019-12-30 2022-07-26 Método para el tratamiento del síndrome de usher y composición del mismo CO2022010430A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019129957 2019-12-30
PCT/CN2020/141501 WO2021136404A1 (zh) 2019-12-30 2020-12-30 一种治疗Usher综合征的方法和其组合物

Publications (1)

Publication Number Publication Date
CO2022010430A2 true CO2022010430A2 (es) 2022-08-09

Family

ID=76687119

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0010430A CO2022010430A2 (es) 2019-12-30 2022-07-26 Método para el tratamiento del síndrome de usher y composición del mismo

Country Status (15)

Country Link
US (1) US20230067480A1 (es)
EP (1) EP4086346A4 (es)
JP (1) JP2023509177A (es)
KR (1) KR20220118512A (es)
CN (1) CN114829598A (es)
AU (1) AU2020418026A1 (es)
BR (1) BR112022012921A2 (es)
CA (1) CA3163280A1 (es)
CO (1) CO2022010430A2 (es)
CR (1) CR20220366A (es)
EC (1) ECSP22059858A (es)
IL (1) IL294260A (es)
MX (1) MX2022008197A (es)
TW (1) TW202138561A (es)
WO (1) WO2021136404A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021020608A8 (pt) 2019-04-15 2023-03-21 Univ Beijing Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit
PE20220300A1 (es) 2019-07-12 2022-03-09 Univ Beijing Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente
CA3159944A1 (en) 2019-12-02 2021-06-10 David HUSS Therapeutic editing
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD128000A1 (de) 1976-10-19 1977-10-26 Gerhard Wuerker Steuereinrichtung fuer einen zwei hauptpumpen besitzenden hydraulischen antrieb
EP3957735A1 (en) * 2014-03-05 2022-02-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
JP7043082B2 (ja) * 2016-04-25 2022-03-29 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 眼疾患を処置するオリゴヌクレオチド
GB201616202D0 (en) * 2016-09-23 2016-11-09 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of eye deisease
JP7402163B2 (ja) * 2017-12-21 2023-12-20 クリスパー セラピューティクス アーゲー ２ａ型アッシャー症候群の処置のための材料および方法
WO2019183641A1 (en) * 2018-03-23 2019-09-26 Massachusetts Eye And Ear Infirmary Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome
JP7252328B2 (ja) 2018-10-12 2023-04-04 北京大学 Ｒｎａを編集する方法および組成物
BR112021020608A8 (pt) * 2019-04-15 2023-03-21 Univ Beijing Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit

Also Published As

Publication number Publication date
JP2023509177A (ja) 2023-03-07
CN114829598A (zh) 2022-07-29
US20230067480A1 (en) 2023-03-02
BR112022012921A2 (pt) 2022-09-06
WO2021136404A1 (zh) 2021-07-08
AU2020418026A1 (en) 2022-08-18
EP4086346A1 (en) 2022-11-09
TW202138561A (zh) 2021-10-16
EP4086346A4 (en) 2024-03-20
MX2022008197A (es) 2022-08-02
CR20220366A (es) 2022-11-28
IL294260A (en) 2022-08-01
CA3163280A1 (en) 2021-07-08
KR20220118512A (ko) 2022-08-25
ECSP22059858A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
CO2022010430A2 (es) Método para el tratamiento del síndrome de usher y composición del mismo
CL2021000880A1 (es) Métodos y composiciones para editar arn
CO2022014527A2 (es) Método y fármaco para tratar el síndrome de hurler
CO2021015214A2 (es) Métodos y composiciones para editar ácidos ribonucleicos (arn)
EA201892810A1 (ru) Гибридные последовательности нуклеиновых кислот для геномной инженерии
PE20230037A1 (es) Metodo basado en tecnologia leaper para el tratamiento de mucopolisacaridosis ih y composicion
BR112021018159A2 (pt) Método para gerar uma molécula de rna com atividade de silenciamento, célula geneticamente modificada, planta geneticamente modificada, célula vegetal, planta, semente, métodos de produção de uma planta, de tratamento de uma doença e de introdução da atividade de silenciamento
AR077809A1 (es) Organismos homocigotas para una modificacion dirigida
Yan et al. The complete mitochondrial genome sequence of the western flower thrips Frankliniella occidentalis (Thysanoptera: Thripidae) contains triplicate putative control regions
AR103446A1 (es) Método para modificar con precisión una planta a través de la expresión transitoria de genes
MX2022000497A (es) Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente.
AR114740A1 (es) Métodos y composiciones para mejorar la solubilización del fosfato
AR062336A1 (es) Recombinacion de homologos mediada por nucleasas en dedo de zinc
AR069894A1 (es) Plantas con mayor rendimiento produciendo un knock out (silenciamiento) en genes relacionados con la eficiencia en el uso de nitrogeno (ko nue)"
AR047166A1 (es) Promotor de metalotioneina de maiz
AR073602A1 (es) Metodo para producir un aditivo para la degradacion enzimatica de micotoxinas y aditivo y uso del mismo
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
BR112021018120A2 (pt) Métodos de produção de uma molécula de dsrna longo, de produção de uma planta tolerante ou resistente a pragas e de produção de uma planta ou célula vegetal, método para gerar uma planta tolerante, planta, célula e semente
BR112022001230A2 (pt) Estratégia de design de doador para edição de genoma crispr-cas9
CO2021014746A2 (es) Método para tratar distrofia muscular por direccionamiento del gen dmpk
ATE482720T1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
BR112022002889A2 (pt) Método para tratar distrofia muscular tendo como alvo o gene lama1
AR047590A1 (es) Alteracion de la estructura de la raiz durante el desarrollo de la planta
AR113432A1 (es) Integración dirigida de ácidos nucleicos
AR115152A1 (es) Elementos reguladores de plantas y métodos de uso de los mismos